{
    "clinical_study": {
        "@rank": "10011", 
        "acronym": "IMPACT", 
        "arm_group": [
            {
                "arm_group_label": "ELVR with Endobronchial Valves", 
                "arm_group_type": "Experimental", 
                "description": "Endoscopic Lung Volume Reduction with Zephyr Endobronchial Valve"
            }, 
            {
                "arm_group_label": "Standard of Care", 
                "arm_group_type": "No Intervention", 
                "description": "Patients will receive optimal drug therapy and medical management according to clinical practice."
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this prospective, randomized, controlled study is to assess and compare the\n      efficacy of the Zephyr endobronchial valves vs. Standard of Care (SoC) in patients suffering\n      from COPD with Homogeneous Emphysema. The primary objective is the variation of FEV1 between\n      baseline and 3-month follow-up visit. The secondary objectives will evaluate quality of\n      life, exercise capacity, dyspnea (including BODE index) changes, target lobe volume\n      reduction, as well as safety outcomes."
        }, 
        "brief_title": "Improving Patient Outcomes by Selective Implantation of the Zephyr EBV - Study", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "COPD Patients With Homogeneous Emphysema", 
            "Endoscopic Lung Volume Reduction With Endobronchial Valve"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Emphysema", 
                "Pulmonary Emphysema"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Homogeneous emphysema\n\n          -  15% < or = FEV1 < or = 45% predicted\n\n          -  TLC > 100% predicted\n\n          -  RV > or = 200% predicted\n\n          -  6-MWT > or = 150 m\n\n          -  Non-smoker > 8 weeks prior to study entry\n\n          -  Absence of Collateral Ventilation in the target lobe\n\n        Exclusion Criteria:\n\n          -  Active pulmonary infection\n\n          -  More than 3 exacerbations with hospitalizations over the past 12 months\n\n          -  Pulmonary hypertension (sPAP > 45 mmHg)\n\n          -  MI or other relevant CV events in the past 6 months\n\n          -  Alpha-1 antitrypsin deficiency\n\n          -  Bronchiectasis\n\n          -  Prior LVR or LVRS procedure\n\n          -  > 20% difference in perfusion between right and left lung\n\n          -  Hypercapnia (paCO2 > 55 mmHg\n\n          -  Asthma\n\n          -  Use of more than 25 mg/day prednisolone or equivalent\n\n          -  Severe bullous emphysema\n\n          -  Systemic or malignant disease with high death probability within 12 months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "56", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02025205", 
            "org_study_id": "630-0014"
        }, 
        "intervention": {
            "arm_group_label": "ELVR with Endobronchial Valves", 
            "description": "Endoscopic Lung Volume Reduction with Zephyr Endobronchial Valve", 
            "intervention_name": "Endobronchial Valve", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 23, 2014", 
        "number_of_arms": "2", 
        "official_title": "A Multicentre, Prospective, Randomized, Controlled Investigation of Endobronchial Valve (EBV) Therapy vs. Standard of Care (SoC) in Homogeneous Emphysema", 
        "overall_contact": {
            "email": "elisabeth.liljensten@devicia.se", 
            "last_name": "Elisabeth Liljensten, DDS, PhD", 
            "phone": "0046-723 61 1968"
        }, 
        "overall_official": {
            "affiliation": "Ludwig-Boltzmann-Institute for COPD and Respiratory Epidemiology Otto-Wagner-Spital 1140 Wien / Austria", 
            "last_name": "Arschang Valipour, MD, PhD, FCCP", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Austria: Austrian Medicines and Medical Devices Agency", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Netherlands: Medical Ethics Review Committee (METC)"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in Forced Expiratory Volume in 1 s (FEV1)", 
            "safety_issue": "No", 
            "time_frame": "At baseline and after 3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02025205"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in Quality of life (SGRQ, CAT, EQ-5D)", 
                "safety_issue": "Yes", 
                "time_frame": "At baseline and after 3 and 6 months"
            }, 
            {
                "measure": "Change in Exercise Capacity (6-MWT)", 
                "safety_issue": "No", 
                "time_frame": "At baseline and after 3 and 6 months"
            }, 
            {
                "measure": "Change in Dyspnea (mMRC)", 
                "safety_issue": "Yes", 
                "time_frame": "At baseline and after 3 and 6 months"
            }, 
            {
                "measure": "Adverse Events and Serious Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "At each visits"
            }
        ], 
        "source": "Pulmonx, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pulmonx International S\u00e0rl", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}